Joaquin Martinez-Lopez

Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104)

Purpose of the Study: Despite recent therapeutic advances, multiple myeloma (MM) remains incurable. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly c...

Yvonne A. Efebera ;

Miquel Granell ;

Paul G. Richardson ;

Roman Hajek ;

Maria-Victoria Mateos ;

Albert Oriol ;

Jacques Delaunay ;

Katell Le Du ;

Jean-Richard Eveillard ;

Lionel Karlin ;

Vladimir Maisnar ;

Joaquin Martinez-Lopez ;

Maxim Norkin ;

Jan Staub ;

Catriona Byrne ;

Malin Sydvander ;

Enrique M. Ocio ;

Vincent Ribrag , MD;

Ludk Pour ;

10/22/2019

Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis

Introduction:Achievement of minimal residual disease negativity (MRD‚Äì) status in multiple myeloma (MM) is associated with improved progression-free survival (PFS) and overall survival. ...

Nelson Castro ;

Tomas Pika ;

Javier De la Rubia ;

Angelo Maiolino ;

Anthony Reiman ;

Thomas G. Martin III, MD;

Sylvia Marion ;

Joseph Mikhael , MD, MEd, FRCPC;

Roman Hajek ;

Sosana Delimpasi ;

Joaquin Martinez-Lopez ;

Sandrine Mace ;